Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Lizhu Gene passed the 2019 international tumor ctDNA gene mutation detection inter-laboratory quality assessment with full marks
Published Time：
2019-08-06
Recently, the National Health Commission Clinical Laboratory Center announced the results of the 2019 international inter-laboratory quality assessment of tumor circulating DNA (ctDNA) gene mutation detection. Lizhu Gene once again passed with a perfect score!
The international inter-laboratory quality assessment project for tumor circulating DNA (ctDNA) gene mutation detection is jointly conducted by the National Health Commission Clinical Laboratory Center and the Royal College of Pathologists of Australia. All quality assessment samples were prepared by the National Health Commission Clinical Laboratory Center. Participating units include laboratories in China and Australia that conduct tumor circulating DNA (ctDNA) mutation detection. This time, Lizhu Gene's perfect score in the 2019 international inter-laboratory quality assessment of tumor circulating DNA (ctDNA) gene mutation detection further reflects Lizhu Gene's standardized laboratory management system, rigorous experimental spirit, and excellent ctDNA gene mutation detection capabilities; at the same time, we will continue to strive to provide scientific and accurate theoretical basis for clinical diagnosis and treatment with our professional technical strength.
| Inter-laboratory Quality Assessment |
Inter-laboratory quality assessment (EQA) refers to the analysis of the same sample by multiple laboratories. The National Health Commission Clinical Laboratory Center collects, analyzes, and feeds back the laboratory test results, evaluating the quality of the laboratory's routine work, observing the accuracy of the experiments, and establishing comparability between the analysis results of various laboratories. Inter-laboratory quality assessment is an important means for clinical laboratories to ensure and improve testing quality, and it is also a basic requirement for the administrative management of clinical laboratories in medical institutions and laboratory accreditation. Participating in inter-laboratory quality assessment can provide objective evidence to evaluate whether the data issued by the laboratory is reliable and effective.
| About Tumor Circulating DNA Mutation Detection |
Tumor circulating DNA (ctDNA) is an important target for liquid biopsy. Gene mutation detection based on peripheral blood ctDNA has extremely high clinical application value in early screening, targeted therapy, drug resistance monitoring, recurrence and prognosis monitoring of tumors, and has been widely used in clinical practice. It can be used as the preferred method for tumor patients who cannot obtain tissue samples. ctDNA gene mutation detection has the advantages of being non-invasive, allowing for repeated sampling, and real-time monitoring. However, due to the very low content of ctDNA in the blood and its fragmented form, it poses great difficulties for clinical detection and places higher demands on clinical testing institutions. The result of this international inter-laboratory quality assessment of tumor circulating DNA (ctDNA) gene mutation detection is further proof of Lizhu Gene's excellent detection capabilities in ctDNA gene mutation detection.
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.